Waltham, Mass. — BostonGene has been named a Diamond winner in the 2026 Pinnacle Awards for Healthcare for its AI-driven work in oncology drug prediction and drug development decision-making.
The Waltham-based company, which develops AI models for tumor and immune biology, was recognized in the Innovator in Biotech Solutions category. The award highlights BostonGene’s use of multimodal AI to improve development decisions, reduce risk and accelerate the delivery of therapies to patients.
The Pinnacle Awards recognize organizations advancing medical technology and care delivery. BostonGene said the Diamond-tier honor reflects its work to improve how critical drug development decisions are made, including decisions that affect clinical success, costs and timelines.
BostonGene said drug development depends on a series of high-stakes choices, including what therapies to develop, which patients to treat and how to design clinical trials. The company addresses those challenges by modeling disease as a dynamic biological system and simulating how tumors and the immune system may respond to treatment.
The company’s platform integrates multimodal data, including genomic, transcriptomic, immune, clinical and imaging signals, to help pharmaceutical partners make more informed decisions before clinical trials begin.
BostonGene said the approach can help partners identify optimal indications, refine patient selection, design more effective trials and better understand mechanisms of response and resistance. The company said this shifts drug development from retrospective analysis toward forward-looking decision-making, with the goal of improving the probability of success while reducing development cost and risk.
“This recognition reflects a broader shift in the industry,” said Andrew Feinberg, President and CEO at BostonGene. “Drug development is not a data problem, it is a decision problem. By modeling biology and simulating response to treatment, we help our partners make better decisions before trials begin, which is where outcomes are determined.”
